Annals of Hematology

, Volume 90, Issue 12, pp 1409–1418

Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

  • Ji-Won Kim
  • Byung-Su Kim
  • Soo-Mee Bang
  • Inho Kim
  • Dong Hwan Kim
  • Won Seog Kim
  • Deok-Hwan Yang
  • Je-Jung Lee
  • Je-Hwan Lee
  • Jin Seok Kim
  • Sang-Kyun Sohn
  • Ho-Young Yhim
  • Jae-Yong Kwak
  • Sung-Soo Yoon
  • Jong Seok Lee
  • Seonyang Park
  • Byoung Kook Kim
  • on behalf of the Korean Society of Blood and Marrow Transplantation
Original Article

DOI: 10.1007/s00277-011-1227-y

Cite this article as:
Kim, JW., Kim, BS., Bang, SM. et al. Ann Hematol (2011) 90: 1409. doi:10.1007/s00277-011-1227-y

Abstract

There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.

Keywords

Non-Hodgkin lymphomaStem cell transplantationDonor lymphocyte infusionPerformance statusAlbumin

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Ji-Won Kim
    • 1
    • 2
  • Byung-Su Kim
    • 1
  • Soo-Mee Bang
    • 1
  • Inho Kim
    • 1
    • 2
    • 3
  • Dong Hwan Kim
    • 4
  • Won Seog Kim
    • 4
  • Deok-Hwan Yang
    • 5
  • Je-Jung Lee
    • 5
  • Je-Hwan Lee
    • 6
  • Jin Seok Kim
    • 7
  • Sang-Kyun Sohn
    • 8
  • Ho-Young Yhim
    • 9
  • Jae-Yong Kwak
    • 9
  • Sung-Soo Yoon
    • 1
    • 2
    • 3
  • Jong Seok Lee
    • 1
  • Seonyang Park
    • 1
    • 2
    • 3
  • Byoung Kook Kim
    • 1
    • 2
    • 3
  • on behalf of the Korean Society of Blood and Marrow Transplantation
  1. 1.Department of Internal MedicineSeoul National University College of MedicineSeoulSouth Korea
  2. 2.Cancer Research InstituteSeoul National UniversitySeoulSouth Korea
  3. 3.Clinical Research InstituteSeoul National University HospitalSeoulSouth Korea
  4. 4.Department of Internal MedicineSungkyunkwan University School of MedicineSeoulSouth Korea
  5. 5.Department of Internal MedicineChonnam National University Medical SchoolGwangjuSouth Korea
  6. 6.Department of Internal MedicineUniversity of Ulsan College of MedicineSeoulSouth Korea
  7. 7.Department of Internal MedicineYonsei University College of MedicineSeoulSouth Korea
  8. 8.Department of Internal MedicineKyungpook National University School of MedicineDaeguSouth Korea
  9. 9.Department of Internal MedicineChonbuk National University Medical SchoolJeonjuSouth Korea